FDA Grants Atezolizumab Priority Review as Adjuvant Treatment for Certain Patients With NSCLC
August 3rd 2021According to a press release from Roche, the FDA is reviewing the company’s Biologics License Application under the Real-Time Oncology Review pilot program, which aims to explore a more efficient review process to ensure safe and effective treatments are available to patients as early as possible.
Read More
Novel Drug Combination Serves as Potential Treatment for Acute Myeloid Leukemia
August 3rd 2021MDM2 inhibitors and BET inhibitors, which show limited efficacy against acute myeloid leukemia (AML) as monotherapies, are potent against AML when used in combination, according to a study published in Nature Communications.
Read More
Expert: COVID-19 Vaccine Mandates in Health System Reflect Patient-Centered Approach
August 3rd 2021Anna Legreid Dopp, PharmD, CPHQ, senior director of clinical guidelines and quality improvement at ASHP, said their organization was proud to sign onto a recent statement urging health care organizations to mandate COVID-19 vaccines for their employees.
Watch
Addressing Logistical Challenges of CAR T Therapy Administration in Inpatient, Outpatient Settings
August 2nd 2021Pharmacy Times interviewed Craig Freyer, PharmD, BCOP, and Andrew Lin, PharmD, BCOP, to discuss how to manage the logistical challenges that arise during the administration of CAR T therapy in inpatient and outpatient settings for patients with multiple myeloma.
Watch
Clinical Trial Shows Safety, Efficacy of Monthly Oral Islatravir for HIV-1 Prevention
August 2nd 2021The investigators noted that the levels of islatravir in peripheral blood mononuclear cells remained above the efficacy pharmacokinetics threshold for PrEP for both doses studied (60 mg and 120 mg) for 8 weeks following the last study dose.
Read More